HEREDITARY DEFECT OF APOLIPOPROTEIN B 100-ANALYSIS OF GROUP OF PATIENTS TREATED WITH STANDARD PERORAL LIPID-LOWERING THERAPY IN ST. ANNE'S UNIVERSITY HOSPITAL BRNO
| Authors | |
|---|---|
| Year of publication | 2016 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Description | Objectives: Patients with familial defective apolipoprotein B-100 (FDB) are in high cardiovascular risk. Reaching the target level of their LDL cholesterol is usually very difficult or even unachievable. The purpose of this study was to determine, how many of our patients reach target level of LDL cholesterol and apolipoprotein B with respect to their initial levels and used hypolipidemic drug. Methods: Only patients with confirmed mutation in apo B gene from our database, treated with hypolipidemic drugs, were included. Excluded were patients with missing data about their lipid levels before start of hypolipidemic therapy (patients treated previously by any other doctors), and non-compliant patients (without regular visits in our centre). Results: Out of 81 patients with FDB, 55 were excluded due to non-compliance or missing data; 26 were included to our study group. During hypolipidemic treatment we decreased level of total cholesterol in men by 35 %, triglycerides by 56 %, LDL cholesterol by 42 % and apo B by 33 %. In women decrease of total cholesterol was 27 %, triglycerides 40 %, LDL cholesterol 34 % and apo B 31 %. Conclusions: In the group of patients with FDB we reduced levels of LDL cholesterol in average by 34-42 % from initial values, depending on gender, used drug and tolerance of treatment. |